Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Nutex HealthNUTX -1.14%75 EBITDA Margin % is 60.30% as of Jun. 2026, which is 84% above its 10-year median of 32.85. GuruFocus rates NUTX with a GF Score™ of 75/100 and a GF Value™ of $82.60 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 670 Healthcare Providers & Services companies, Nutex Health ranks better than 96.87% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Nutex Health's EBITDA for the
three
months ended in Jun. 2026 was $127.1 Mil. Nutex Health's Revenue for the
three
months ended in Jun. 2026 was $210.8 Mil. Therefore, Nutex Health's EBITDA margin for the quarter that ended in Jun. 2026 was 60.30%.
Nutex Health (NAS:NUTX) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Nutex Health EBITDA Margin % Related Terms
Nutex Health EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Nutex Health's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NUTX vs USPH, AMN, GMRS: EBITDA Margin % Comparison
For the Medical Care Facilities subindustry, Nutex Health's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nutex Health EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Nutex Health's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Nutex Health's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nutex Health (NUTX) has a EBITDA Margin % of 60.30% as of Jun. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Nutex Health and its competitors. This is 84% above median its historical median of 32.85. According to the industry distribution chart, Nutex Health ranks #21 out of 670 companies in the Healthcare Providers & Services industry, placing it in the top 3.1%.
Is Nutex Health's EBITDA Margin % too high?
Nutex Health's current EBITDA Margin % of 60.30% is 84% above median its 10-year median of 32.85. The Healthcare Providers & Services industry median EBITDA Margin % is 10.24. Nutex Health's value of 60.30% is 489.2% above this industry median. Based on the distribution chart, Nutex Health ranks #21 out of 670 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Nutex Health has a GF Score™ of 75/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Nutex Health's EBITDA Margin % compare to USPH and AMN?
According to the Healthcare Providers & Services industry distribution chart, Nutex Health ranks #21 out of 670 companies for EBITDA Margin %. This places Nutex Health in the top 3% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 10.24. Nutex Health's value of 60.30% is 489.2% above this benchmark. While the company's 10-year median is 32.85 vs. the industry median of 10.24, Nutex Health has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.24, based on 670 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nutex Health's current EBITDA Margin % of 60.30% is 489.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Nutex Health and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nutex Health's current EBITDA Margin % is 60.30%, which is 84% above median its own 10-year median of 32.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nutex Health stock overvalued right now?
Based on GuruFocus' analysis, Nutex Health (NUTX) is currently considered Significantly Overvalued. The stock's GF Value™ is $82.60, compared to a current price of $191.69 — trading 132.1% above its estimated fair value. The current EBITDA Margin % is 60.30%, which is 84% above median its 10-year median of 32.85 and 489.2% above the Healthcare Providers & Services industry median of 10.24. Nutex Health's overall GF Score™ is 75/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Nutex Health (NUTX), the current EBITDA Margin % is 60.30% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nutex Health (NUTX) Overvalued in 2026?
Based on GuruFocus' analysis, Nutex Health stock appears to be overvalued.
The current stock price of $191.69 is trading 132.1% above its estimated GF Value™ of $82.60.
GuruFocus considers Nutex Health to be Significantly Overvalued.
Key valuation signals for NUTX:
EBITDA Margin %: 60.30% (84% above median its 10-year median of 32.85)
GF Value™: $82.60 vs. price of $191.69 (132.1% above fair value)
Industry Position: 489.2% above the Healthcare Providers & Services median (#21 of 670)
No single metric tells the full story. See the NUTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nutex Health Inc is a physician-led, healthcare services and operations company with various hospital facilities in the U.S. states (hospital division), and a primary care-centric, risk-bearing population health management division. The company has three segments: the hospital division, the PHM division, and the real estate division. The hospital division implements and operates health care models, including micro-hospitals, specialty hospitals and hospital outpatient departments (HOPDs). The population health management (PHM) division owns and operates provider networks such as independent physician associations (IPAs). The Real Estate Entities own the land and hospital buildings which are leased to its hospital entities. The majority of the revenue is derived from the Hospital division.
75GF Score
Get the complete analysis for NUTX
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NUTX has been successfully added to your 
